Since I became chemo-resistant in May this year, and failed to have any response at all to Xtandi, I had blood drawn for prescreening for Galahad trial a few weeks ago (they extract CTC from blood rather than doing an invasive tumour biopsy).
I got back test results yesterday - somatic DNA tested positive to BRCA2 mutation. I will now move onto the main trial. I need to have CT and bone scans to set baseline and then can start taking Niraparib. Hopefully within next 2 weeks.
PTEN mutation was not tested as this trial is restricted to PARP inhibitors. My post-RP biopsy in 2015 showed 5% intraductal PCA and with aggressive growth of cancer since then I assume that I have lost PTEN expression but that is a problem for another day.
Anybody else on Galahad trial, or tried Niraparib? How did it go, and what (if any) side effects did you encounter?
Ever onwards!
Written by
Hazard
To view profiles and participate in discussions please or .
They just presented early results from a similar trial TRITON 2 at the ESMO conference. A similar PARP inhibitor (rucaparib) shrank tumors in about half of the men with somatic or germline BRCA1/2 mutations.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.